Federal Circuit Deals Blow to Actelion in Long-Running Patent Battle Over Veletri® Generic

In a significant precedential ruling, the U.S. Court of Appeals for the Federal Circuit (CAFC) has affirmed a district court decision finding that Mylan Pharmaceuticals did not infringe upon Actelion Pharmaceuticals’ patents for the hypertension drug Veletri®. The decision marks a pivotal moment in the ongoing litigation surrounding pharmaceutical formulation patents, specifically addressing the technical intricacies of chemical property claims—in this case, the measurement of pH in bulk pharmaceutical solutions.

The appellate court’s ruling, authored by Judge Taranto, effectively shuts down Actelion’s attempts to block Mylan’s generic version of the life-saving medication by upholding a strict interpretation of claim language and reinforcing the legal doctrines of prosecution history estoppel and the disclosure-dedication rule.

The Core Facts: A Dispute Over Chemical Definitions

At the heart of the litigation are U.S. Patent Nos. 8,318,802 and 8,598,227, both held by Actelion. These patents protect specific pharmaceutical compositions involving epoprostenol, a potent vasodilator used to treat pulmonary arterial hypertension.

The patent claims specifically recite that the composition is "formed from a bulk solution having a pH of 13 or higher" or "greater than 13." When Mylan sought FDA approval for its generic version via an Abbreviated New Drug Application (ANDA), Actelion initiated a patent infringement lawsuit. Mylan maintained throughout the proceedings that its manufacturing process utilized a bulk solution with a pH level that fell outside the scope of Actelion’s claimed range.

The central conflict became a question of scientific standards: Does a pH reading of "13 or higher" refer to a measurement taken at a standard laboratory temperature (typically 25°C), or does it account for temperature-dependent variations—such as those occurring during cold-chain manufacturing or refrigeration?

A Chronology of the Litigation

The path to the CAFC’s recent decision was long and characterized by rigorous judicial scrutiny of scientific definitions.

• The Initial District Court Ruling: In the first round of litigation, the district court construed the claims to mean a pH of 12.5 or higher, applying standard rounding rules to the claimed figure of 13.
• The 2023 Remand: The Federal Circuit vacated that initial construction, signaling that the lower court had reached its conclusion without sufficient reliance on extrinsic evidence. The appellate court directed that a more robust investigation into the scientific understanding of "pH" in the pharmaceutical industry was required.
• Post-Remand Determination: Following the remand, the district court reassessed the claims and arrived at a new interpretation: "a pH of 13 or higher" was to be construed as 12.98 or higher.
• The Final Appellate Decision: It was undisputed that Mylan’s manufacturing process resulted in a bulk solution with a pH below 12.98. Actelion attempted to argue that if the solution were measured at the cold temperatures used during manufacturing, the pH would indeed cross the threshold of 13. The district court rejected this, and the CAFC affirmed, noting that the claim construction was sound and that no reversible error had occurred.

Supporting Data: Scientific and Legal Analysis

To resolve the impasse, the courts delved deep into both intrinsic and extrinsic evidence.

The Role of Standard Temperature

The CAFC examined the patent specifications and the broader body of chemistry literature. The court noted that the term "alkaline environment" in the patent was defined as having a pH > 7. Crucially, the court recognized that this definition is only scientifically accurate when measured at standard temperature.

The appellate court turned to extrinsic evidence—including the United States Pharmacopeia (USP), standard chemistry textbooks, and expert testimony. The consensus among these sources was clear: when a person of ordinary skill in the art (PHOSITA) in the pharmaceutical industry refers to pH, they are referring to a measurement taken at standard temperature, unless otherwise specified. The court found that the district court had not committed "clear error" in evaluating this evidence.

The Failure of the Equivalents Theory

Beyond literal infringement, Actelion argued that Mylan’s product was an "equivalent" under the Doctrine of Equivalents. Actelion contended that Mylan’s process achieved the same stability as the patented product by reducing hydrogen ion concentration in the same way.

The court systematically dismantled this argument on two fronts:

1. Prosecution History Estoppel: Because Actelion had narrowed its patent claims during the original patent prosecution process to overcome objections, the court held they were legally "estopped" from reclaiming that lost ground by calling it an "equivalent."
2. The Disclosure-Dedication Rule: The CAFC affirmed that Actelion had previously disclosed alternative pH ranges in their filings but failed to claim them. Under the disclosure-dedication rule, subject matter disclosed in a patent application but not claimed is considered dedicated to the public, preventing the patentee from asserting it as an equivalent later in court.

Official Responses and Judicial Reasoning

In his opinion for the court, Judge Taranto emphasized that the patent holder’s own choices during the prosecution of their patents constrained their options in litigation.

"The claim language on its own does not resolve the question of the proper interpretation of ‘a pH of 13 or higher,’" the court wrote, noting that the patent’s internal specifications and the examiner’s statements during the application process did not support Actelion’s broad interpretation. By attempting to rely on temperature-sensitive measurements that deviate from standard industry practice, Actelion sought to expand the scope of its patents beyond what was originally intended at the time of filing.

The court’s refusal to allow "tangential" arguments regarding the amendment of claims effectively closed the door on Actelion’s pursuit of an infringement finding through the Doctrine of Equivalents.

Implications: What This Means for the Pharmaceutical Industry

1. Precision in Claim Drafting

This case serves as a stark warning for patent attorneys and pharmaceutical companies: scientific terms must be defined with extreme precision. When a claim relies on a variable like pH, the patent specification must explicitly state the conditions under which that measurement is taken (e.g., temperature, pressure, or solvent). Failing to do so leaves the patent vulnerable to interpretations based on industry standards that may not align with the patentee’s proprietary goals.

2. The Limits of the Doctrine of Equivalents

The decision reinforces the strength of the disclosure-dedication rule. Pharmaceutical firms often disclose various embodiments in their patent applications to ensure comprehensive coverage. However, this ruling highlights that if those alternatives are not explicitly claimed, they cannot be retrieved through the Doctrine of Equivalents. This forces companies to be more strategic and aggressive during the drafting phase rather than relying on litigation to capture missed technical variations.

3. Impact on Generic Competition

For generic manufacturers like Mylan, this ruling is a major victory. It provides a blueprint for defending against "evergreening" strategies—where brand-name drug manufacturers use narrow, technically specific patents to delay the entry of lower-cost generic alternatives. By successfully arguing that their manufacturing processes do not meet the stringent, standard-temperature-based chemical definitions of the original patent, Mylan has cleared a significant legal hurdle to maintaining its market position.

4. Setting a Precedent for "Standard Conditions"

The CAFC’s affirmation that "pH" carries an inherent implication of "standard temperature" in the pharmaceutical context creates a clear precedent for future litigation. Courts are now more likely to rely on the USP and standard chemical textbooks as the baseline for interpreting chemical properties in patent claims, reducing the room for creative, temperature-dependent interpretations that some patent holders may use to expand their monopoly.

Conclusion

The CAFC’s decision is a masterclass in the application of intellectual property doctrine to chemical engineering. By holding Actelion to the language of its own patents and the standard definitions accepted by the scientific community, the court has underscored the importance of clarity in innovation. For patients, the ruling paves the way for continued access to generic hypertension treatments, reinforcing the balance the patent system must strike between rewarding innovation and fostering competitive, affordable pharmaceutical markets.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. The views expressed herein are those of the author and do not necessarily reflect the position of any firm or legal institution.